Amsterdam, The Netherlands, April 7, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that at its next General Meeting of Shareholders, the Kiadis Pharma Supervisory Board will nominate Dr.… Continue reading Kiadis Pharma proposes Robert Soiffer and Berndt Modig as its new Supervisory Board members
Author: Willem van Lawick
Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101™
– Significant increase in Overall Survival and reduction in Transplant Related Mortality observed in comparison to a historical control group – Zero patients developed grade III-IV acute Graft-versus-Host-Disease upon infusion of ATIR101™ – Initiation of a randomised Phase III trial in the second half of 2016 – Management will host a webcast to discuss the… Continue reading Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101™
Top-line data from all patients on the primary endpoint of Kiadis Pharma’s Phase II trial with ATIR101TM selected for oral presentation at 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation
~ Additional ATIR101TM data also selected for three poster presentations at EBMT ~ Amsterdam, The Netherlands, March 1, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that key data… Continue reading Top-line data from all patients on the primary endpoint of Kiadis Pharma’s Phase II trial with ATIR101TM selected for oral presentation at 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation
Kiadis Pharma and The Leukemia & Lymphoma Society enter partnership for the development of ATIR101™ in ALL and AML patients
~ LLS will fund the Phase II development via an equity investment in Kiadis Pharma ~ Amsterdam, The Netherlands, February 1, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces… Continue reading Kiadis Pharma and The Leukemia & Lymphoma Society enter partnership for the development of ATIR101™ in ALL and AML patients
Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London
Funding will enable new intranasal vaccine SynGEM® to be tested in phase I and IIa human clinical trials Groningen, the Netherlands, January 20, 2016 –Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation and needle-free human vaccines for infectious diseases, today announced that it has secured a €3.7 million… Continue reading Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London
